24 March 2022 - NICE has published evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.

Nivolumab with ipilimumab is recommended as an option for untreated adults with advanced renal cell carcinoma:

• whose disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and
• only if BMS provides nivolumab with ipilimumab according to the commercial arrangement

Read NICE technology appraisal guidance for nivolumab